Practical Management of Anticoagulants in Family Medicine after Orthopedic Surgery

References

• . Geerts WH, Bergqvist D, Pineo GF, ; American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133( 6 suppl):381S–453S
   PubMed Web of Science ®Google Scholar
• . Warwick D, Friedman RJ, Agnelli G, . Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br. 2007;89(6):799–807
   PubMedGoogle Scholar
• . Canales JF, Ferguson JJ. Low-molecular-weight heparins: mechanisms, trials, and role in contemporary interventional medicine. Am J Cardiovasc Drugs. 2008;8(1):15–25
   PubMedGoogle Scholar
• . Samama MM, Gerotziafas GT, Elalamy I, . Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb. 2002;32(5–6):218–224
   PubMedGoogle Scholar
• . Iorio R, Robb WJ, Healy WL, . Orthopaedic workforce and volume assessment for total hip and knee replacement in the United States: preparing for an epidemic. J Bone Joint Surg Am. 2008;90(7):1598–1605
   PubMedGoogle Scholar
• . Wilson NA, Schneller ES, Montgomery K, Bozic KJ. Hip and knee implants: current trends and policy considerations. Health Aff (Millwood). 2008;27(6):1587–1598
   PubMedGoogle Scholar
• . Geerts WH, Pineo GF, Heit JA, . Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126( 3 suppl):338S–400S
   PubMed Web of Science ®Google Scholar
• . Falck—Ytter Y, Francis CW, Johanson N, . Prevention of VTE in Orthopedic Surgery Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141( suppl):e278S–e325S
   PubMed Web of Science ®Google Scholar
• . Lin P. Reviewing the reality: why we need to change. Eur Heart J. 2005;7:E15–E20
   Web of Science ®Google Scholar
• . Siguret V, Pautas E, Gouin—Thibault I. Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin. Vitam Horm. 2008;78:247–264
   PubMedGoogle Scholar
• . Friedman RJ, Gallus AS, Cushner FD, ; Global Orthopaedic Registry Investigators. Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin. 2008;24(1):87–97
   PubMed Web of Science ®Google Scholar
• . Robert—Ebadi H, Le Gal G, Righini M. Use of anticoagulants in elderly patients: practical recommendations. Clin Interv Aging. 2009;4:165–177
   PubMed Web of Science ®Google Scholar
• . van Walraven C, Jennings A, Oake N, . Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest. 2006;129(5):1155–1166
   PubMed Web of Science ®Google Scholar
• . Upshur RE, Papoushek C, Macdonald D, Dantas G. Short report: managing anticoagulation. Comparison of results at three primary care centres. Can Fam Physician. 2003;49:181–184
   PubMedGoogle Scholar
• . Ansell J, Hollowell J, Pengo V, . Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the International Study of Anticoagulation Management (ISAM). J Thromb Thrombolysis. 2007;23(2):83–91
   PubMedGoogle Scholar
• . Rose AJ, Ozonoff A, Grant RW, Henault LE, Hylek EM. Epidemiology of subtherapeutic anticoagulation in the United States. Circ Cardiovasc Qual Outcomes. 2009;2(6):591–597
   PubMed Web of Science ®Google Scholar
• . Turpie AG. Oral, direct Factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol. 2007;27(6):1238–1247
   PubMed Web of Science ®Google Scholar
• . Perzborn E, Strassburger J, Wilmen A, . In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitor. J Thromb Haemost. 2005;3(3):514–521
   PubMed Web of Science ®Google Scholar
• . Eriksson BI, Borris L, Dahl OE, ; ODIXa-HIP Study Investigators. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost. 2006;4(1):121–128
   PubMedGoogle Scholar
• . Hoppensteadt D, Neville B, Maddenini J, . Comparative anticoagulant and antiprotease actions of BAY 59-7939—an oral, direct Factor Xa inhibitor—and enoxaparin and fondaparinux. Pathophysiol Haemost Thromb. 2004;33( suppl 2); abstract FP39
   Google Scholar
• . Lassen MR, Laux V. Emergence of new oral antithrombotics: a critical appraisal of their clinical potential. Vasc Health Risk Manag. 2008;4(6):1373–1386
   PubMedGoogle Scholar
• . Kubitza D, Haas S. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin Investig Drugs. 2006;15(8):843–855
   PubMed Web of Science ®Google Scholar
• . Walenga JM, Jeske WP, Samama MM, Frapaise FX, Bick RL, Fareed J. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Expert Opin Investig Drugs. 2002;11(3): 397–407
   PubMed Web of Science ®Google Scholar
• . Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med. 2005;353(10):1028–1040
   PubMed Web of Science ®Google Scholar
• . Franchini M, Mannucci PM. A new era for anticoagulants. Eur J Intern Med. 2009;20(6):562–568
   PubMedGoogle Scholar
• . Weitz JI. New oral anticoagulants in development. Thromb Haemost. 2010;103(1):62–70
   PubMed Web of Science ®Google Scholar
• . Dubois EA, Cohen AF. Dabigatran etexilate. Br J Clin Pharmacol. 2010;70(1):14–15
   PubMedGoogle Scholar
• . Business Wire. Pradaxa® (dabigatran etexilate) approved in Japan for stroke prevention in atrial fibrillation [press release]. January 21, 2011. http://www.businesswire.com/news/home/20110121005341/en/PRAZAXA%C2%AE-dabigatran-etexilate-Approved-Japan-Stroke-Prevention. Accessed May 7, 2012
   Google Scholar
• . Xarelto (rivaroxaban) [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2011
   Google Scholar
• . Eliquis [package insert]. Middlesex, UK: Bristol-Myers Squibb/Pfizer EEIG; 2011
   Google Scholar
• . Goldhaber SZ, Leizorovicz A, Kakkar AK, ; ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365(23):2167–2177
   PubMed Web of Science ®Google Scholar
• . Eriksson BI, Dahl OE, Rosencher N, ; RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370(9591):949–956
   PubMed Web of Science ®Google Scholar
• . Eriksson BI, Dahl OE, Rosencher N, . Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5(11):2178–2185
   PubMed Web of Science ®Google Scholar
• . ; RE-MOBILIZE Writing CommitteeGinsberg JS, Davidson BL, Comp PC, . Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24(1):1–9
   Web of Science ®Google Scholar
• . Eriksson BI, Borris LC, Friedman RJ, . Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765–2775
   PubMed Web of Science ®Google Scholar
• . Kakkar AK, Brenner B, Dahl OE, . Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372(9632):31–39
   PubMed Web of Science ®Google Scholar
• . Lassen MR, Ageno W, Borris LC, . Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776–2786
   PubMed Web of Science ®Google Scholar
• . Turpie AG, Lassen MR, Davidson BL, . Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373(9676):1673–1680
   PubMed Web of Science ®Google Scholar
• . Turpie AG, Lassen MR, Eriksson BI, . Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost. 2011;105(3):444–453
   PubMed Web of Science ®Google Scholar
• . Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361(6):594–604
   PubMed Web of Science ®Google Scholar
• . Lassen MR, Raskob GE, Gallus A, . Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375(9717):807–815
   PubMed Web of Science ®Google Scholar
• . Lassen MR, Gallus A, Raskob GE, . Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363(26):2487–2498
   PubMed Web of Science ®Google Scholar
• . Huang J, Cao Y, Liao C, Wu L, Gao F. Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials. Thromb Haemost. 2011;105(2):245–253
   PubMed Web of Science ®Google Scholar
• . Wiedermann CI, Stockner I. Warfarin-induced bleeding complications—clinical presentation and therapeutic options. Thromb Res. 2008;122( suppl 2):S13–S18
   PubMedGoogle Scholar
• . Stangier J, Rathgen K, Stahle H, . The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64(3):292–303
   PubMed Web of Science ®Google Scholar
• . Mueck W, Becka M, Kubitza D, Voith B, Zuehlsdorf M. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban—an oral direct factor Xa inhibitor—in healthy subjects. Int J Clin Pharmacol Ther. 2007;45(6):335–344
   PubMedGoogle Scholar
• . Wong PC, Crain EJ, Xin B, . Apixaban, an oral direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008;6(5):820–829
   PubMed Web of Science ®Google Scholar
• . van Ryn J, Stangier J, Haertter S, . Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116–1127
   PubMed Web of Science ®Google Scholar
• . Gruber A, Marzec UN, Buetehorn U, . Potential of activated prothrombin complex concentrate and activated Factor VII to reverse the anticoagulant effects of rivaroxaban in primates [abstract]. Blood. 2008;112:3825
   Web of Science ®Google Scholar
• . Eerenberg ES, Kamphuisen PW, Sijpkens MK, . Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124(14):1573–1579
   PubMed Web of Science ®Google Scholar
• . Perzborn E, Tinel H. FEIBA reverses the effects of a high dose of rivaroxaban in rats. Presented at: XXII Congress of the International Society on Thrombosis and Haemostasis; Boston, MA; July 11–16, 2009. A40
   Google Scholar